ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This randomized four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom™ and DuraSite® (vehicle), each administered twice-daily. ISV-303 combines a lower dose (0.075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY™/Xibrom (bromfenac ophthalmic solution) 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision’s proprietary DuraSite drug delivery technology.
